review · Vaccines
Multidrug-resistant Acinetobacter baumannii is an escalating global concern, particularly within hospital intensive care units where it causes severe healthcare-associated infections. The proliferation of this bacterium is largely driven by the overuse of antimicrobial medications alongside insufficient infection control measures. Patients suffering from these infections frequently endure extended hospital stays and face heightened rates of morbidity and mortality. In response to increasing drug resistance, researchers are examining the epidemiology, risk factors, and resistance patterns of the pathogen, with particular attention given to Saudi Arabia. Scientific efforts have increasingly focused on vaccine development by applying core knowledge of bacterial pathology. While candidate vaccines have demonstrated promising protection in animal testing, their effectiveness in human populations is not yet established. Ongoing research aims to address development hurdles and establish dependable preventive interventions.
Hospital-acquired infections caused by drug-resistant bacteria pose a critical threat to patients in intensive care units, driving up death rates and healthcare costs. Understanding how Acinetobacter baumannii spreads and identifying current bottlenecks in vaccine development helps healthcare systems and researchers focus resources on creating viable preventative treatments where standard antibiotics are failing.
The application focus is preventative vaccines for healthcare environments and intensive care units. Potential end users include clinical providers and high-risk hospitalised patients. The technology is at an early stage of development, as candidate vaccines have succeeded in animal models but have not yet demonstrated efficacy in human trials.
AI-generated from the published abstract. Always read the original work before citing.
There is growing concern among healthcare providers worldwide regarding the prevalence of multidrug-resistant Acinetobacter baumannii (A. baumannii). Some of the worst hospital-acquired infections, often in intensive care units (ICUs), are caused by this bacterial pathogen. In recent years, the rise in multidrug-resistant A. baumannii has been linked to the overuse of antimicrobial drugs and the lack of adequate infection control measures. Infections caused by this bacterial pathogen are the result of prolonged hospitalization and ICU stays, and they are associated with increased morbidity and mortality. This review outlines the epidemiology, risk factors, and antimicrobial resistance associated with A. baumannii in various countries, with a special focus on the Kingdom of Saudi Arabia. In response to the growing concern regarding this drug-resistant bacteria, fundamental information about its pathology has been incorporated into the development of vaccines. Although these vaccines have been successful in animal models, their effectiveness in humans remains unproven. The review will discuss the development of A. baumannii vaccines, potential related obstacles, and efforts to find an effective strategy against this pathogen.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/vaccines11071171
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
